NCCN Myelodysplastic Panel Members

* Peter L. Greenberg, MD/Chair ‡
  Stanford Comprehensive Cancer Center

* Eyal Attar, MD † ‡
  Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

* Minoo Battiwalla, MD
  Roswell Park Cancer Institute

* John M. Bennett, MD ♠ †
  Consultant

* Clara D. Bloomfield, MD †
  Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

* Carlos M. DeCastro, MD †
  Duke Comprehensive Cancer Center

* H. Joachim Deeg, MD † ‡
  Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

* Harry P. Erba, MD, PhD † ‡
  University of Michigan Comprehensive Cancer Center

* James M. Foran, MD †
  University of Alabama at Birmingham Comprehensive Cancer Center

* Guillermo Garcia-Manero, MD
  The University of Texas M. D. Anderson Cancer Center

* Steven D. Gore, MD † ‡
  The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

* David Head, MD ≠
  Vanderbilt-Ingram Cancer Center

  Lori J. Maness, MD ‡
  UNMC Eppley Cancer Center at The Nebraska Medical Center

* Michael Millenson, MD ♠ †
  Fox Chase Cancer Center

* Stephen D. Nimer, MD † ‡
  Memorial Sloan-Kettering Cancer Center

* Margaret R. O'Donnell, MD ‡
  City of Hope

* Hussain I. Saba, MD, PhD †
  H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida

* Paul J. Shami, MD ‡
  Huntsman Cancer Institute at the University of Utah

* Kathy Spiers, MD
  St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute

* Richard M. Stone, MD ‡
  Dana-Farber/Partners CancerCare

* Martin S. Tallman, MD ‡
  Robert H. Lurie Comprehensive Cancer Center of Northwestern University

* Peter Westervelt, MD PhD †
  Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

* Writing Committee Member
  † Medical Oncology
  ‡ Hematology/Hematology Oncology
  ♠ Internal Medicine
  ≠ Pathology
Table of Contents

NCCN Myelodysplastic Syndromes Panel Members
Summary of Guidelines Updates
Initial Evaluation (MDS-1)
The French-American-British (FAB), International Prognostic Scoring System (IPSS) and World Health Organization (WHO) Classification for de Novo MDS (MDS-2, 3)
Treatment of LOW INT-1 (MDS-4)
Treatment of INT-2, HIGH (MDS-5)
Evaluation and Treatment of Related Anemia (MDS-6)
Supportive Care for MDS (MDS-A)

For help using these documents, please click here

Discussion
References

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, click here:
nccn.org/clinical_trials/physician.html

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus

Guidelines Index
Print the Myelodysplastic Syndromes Guideline

These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2008.
Summary of the Guidelines updates

MDS-1
• Consider molecular testing for JAK2 mutation in patients with thrombocytosis was added to the initial evaluation as helpful in some clinical circumstances.

MDS-4
• Lenalidomide was added as a treatment recommendation to be considered for symptomatically anemic non-del(5q) patients whose anemia did not respond to initial therapy.

MDS-5
• Footnote “v” was revised to state “Based on age, performance status, major comorbid conditions, psychosocial status and availability of caregiver.”
INITIAL EVALUATION

Cytopenia(s), suspect myelodysplasia

Required:
- H&P
- CBC, platelets, differential, reticulocyte count
- Examination of peripheral smear
- Bone marrow aspiration with iron stain + biopsy + cytogenetics
- Serum erythropoietin (prior to RBC transfusion)
- RBC folate, and serum B12
- Serum ferritin ± iron, TIBC
- Documentation of transfusion history

Diagnosis of MDS established based on morphological and clinical criteria\(^a,b\)

Helpful in Some Clinical Situations:
- HLA typing if hemopoietic stem cell transplant (HSCT) candidate\(^c\)
- HLA typing if indicated for platelet support
- Consider HLA-DR15 typing\(^d\)
- HIV testing if clinically indicated
- Evaluate CMML patients for 5q31-33 translocations and/or PDGFR\(\beta\) gene rearrangements
- Consider molecular testing for JAK2 mutation in patients with thrombocytosis
- Consider flow cytometry to evaluate for PNH clone or to assess possible large granular lymphocytic (LGL) disease
- Consider additional genetic screening for patients with familial cytopenias\(^e\)

Consider observation to document indolent course vs marked progression of severe cytopenia

\(^a\)Confirm diagnosis of MDS according to FAB and WHO criteria for classification with application of IPSS. See Classification Systems (MDS-2 and MDS-3). Percentage of marrow myeloblasts should be reported.

\(^b\)Patients with significant cytopenias and karyotypes t(8;21), t(15;17), and/or inv(16) or variants should be considered AML. (See NCCN AML Guidelines).

\(^c\)Family HLA - evaluation to include all full siblings; unrelated evaluation to include high resolution allele level typing for HLAA, B, C, DR, DQ.

\(^d\)To aid the evaluation for improved response to immunosuppressive therapy.

\(^e\)To assess possible Fanconi anemia or dyskeratosis congenita.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### FAB Classification of MDS<sup>f,g</sup>

<table>
<thead>
<tr>
<th>FAB subtype</th>
<th>% of Peripheral blasts</th>
<th>% of Bone marrow blasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory anemia (RA)</td>
<td>&lt; 1</td>
<td>&lt; 5</td>
</tr>
<tr>
<td>Refractory anemia with ringed sideroblasts (RARS)</td>
<td>&lt; 1</td>
<td>&lt; 5</td>
</tr>
<tr>
<td>Refractory anemia with excess blasts (RAEB)</td>
<td>&lt; 5</td>
<td>5-20</td>
</tr>
<tr>
<td>Refractory anemia with excess blasts in transformation (RAEB-t)</td>
<td>≥ 5</td>
<td>21-30</td>
</tr>
<tr>
<td>Chronic myelomonocytic leukemia (CMML) (&gt; 1,000 monocytes/mcL blood)</td>
<td>&lt; 5</td>
<td>5-20</td>
</tr>
</tbody>
</table>

---

### WHO Classification of MDS<sup>h,i</sup>

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Blood</th>
<th>Bone marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory anemia (RA)</td>
<td>Anemia; no or rare blasts</td>
<td>Erythroid dysplasia only; &lt; 5% blasts; &lt; 15% ringed sideroblasts</td>
</tr>
<tr>
<td>Refractory cytopenia with multilineage dysplasia (RCMD)</td>
<td>Cytopenias (bicytopenia or pancytopenia); no or rare blasts; no Auer rods; &lt; 1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Dysplasia in ≥ 10% of cells in ≥ 2 myeloid cell lines; &lt; 5% blasts; no Auer rods; &lt; 15% ringed sideroblasts</td>
</tr>
<tr>
<td>Refractory anemia with ringed sideroblasts (RARS)</td>
<td>Anemia; no blasts</td>
<td>Erythroid dysplasia only; &lt; 5% blasts; ≥ 15% ringed sideroblasts</td>
</tr>
<tr>
<td>Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)</td>
<td>Cytopenias (bicytopenia or pancytopenia); no or rare blasts; no Auer rods; &lt; 1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Dysplasia in ≥ 10% of cells in ≥ 2 myeloid cell lines; &lt; 5% blasts; no Auer rods; ≥ 15% ringed sideroblasts</td>
</tr>
<tr>
<td>Refractory anemia with excess blasts-1 (RAEB-1)</td>
<td>Cytopenias; &lt; 5% blasts; no Auer rods; &lt; 1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Unilineage or multilineage dysplasia; 5% to 9% blasts; no Auer rods</td>
</tr>
<tr>
<td>Refractory anemia with excess blasts-2 (RAEB-2)</td>
<td>Cytopenias; 5-19% blasts; Auer rods ±; &lt; 1 x 10&lt;sup&gt;9&lt;/sup&gt;/L monocytes</td>
<td>Unilineage or multilineage dysplasia 10% to 19% blasts; Auer rods ±</td>
</tr>
<tr>
<td>Myelodysplastic syndrome, unclassified (MDS-U)</td>
<td>Cytopenias; no or rare blasts; no Auer rods</td>
<td>Unilineage dysplasia in granulocytes or megakaryocytes; &lt; 5% blasts; no Auer rods</td>
</tr>
<tr>
<td>MDS associated with isolated del(5q)</td>
<td>Anemia; &lt; 5% blasts; platelets normal or increased</td>
<td>Normal to increased megakaryocytes with hypolobated nuclei; &lt; 5% blasts; no Auer rods; isolated del (5q)</td>
</tr>
</tbody>
</table>

---

<sup>f</sup>FAB = French-American-British classification system of MDS.
<sup>h</sup>WHO = World Health Organization classification system of MDS.
<sup>i</sup>This research was originally published in Blood. Vardiman JW, Harris NL, Bruning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302. © the American Society of Hematology.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
IPSS\(^{j,k,l}\)

<table>
<thead>
<tr>
<th>Survival and AML evolution</th>
<th>Score value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prognostic variable</td>
<td>0</td>
</tr>
<tr>
<td>Marrow blasts (%)(^{m})</td>
<td>&lt; 5</td>
</tr>
<tr>
<td>Karyotype(^{n})</td>
<td>Good</td>
</tr>
<tr>
<td>Cytopenia(^{o})</td>
<td>0/1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk category (% IPSS pop.)</th>
<th>Overall score</th>
<th>Median survival (y) in the absence of therapy</th>
<th>25% AML progression (y) in the absence of therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW (33)</td>
<td>0</td>
<td>5.7</td>
<td>9.4</td>
</tr>
<tr>
<td>INT-1 (38)</td>
<td>0.5-1.0</td>
<td>3.5</td>
<td>3.3</td>
</tr>
<tr>
<td>INT-2 (22)</td>
<td>1.5-2.0</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>HIGH (7)</td>
<td>≥ 2.5</td>
<td>0.4</td>
<td>0.2</td>
</tr>
</tbody>
</table>

\(^{j}\)IPSS = International Prognostic Scoring System


\(^{m}\)Patients with 20-30 % blasts may be considered as MDS or AML.

\(^{n}\)Cytogenetics: Good = normal, -Y alone, del(5q) alone, del(20q) alone; Poor = complex (≥ 3 abnormalities) or chromosome 7 anomalies; Intermediate = other abnormalities. [This excludes karyotypes t(8;21), inv16, and t(15;17), which are considered to be AML not MDS.]

\(^{o}\)Cytopenias: neutrophil count <1,800/mcL, platelets < 100,000/mcL, Hb < 10g/dL.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**IPSS CATEGORY**

**LOW, INT-1**

- **Symptomatic anemia**
  - Serum Epo ≤ 500 mU/ml
    - **Del(5q) ± other cytogenetic abnormalities** → **Lenalidomide** → *No response* → **Follow appropriate pathway below**
    - Epoptin alfa (rHu EPO) or Darbepoetin alfa ± G-CSF
      - **Good probability to respond to IST**
    - Antithymocyte globulin (ATG) or Cyclosporin A
      - **No response**
      - **Azacytidine/decitabine** or **Clinical trial**
      - **No response**
      - **Azacytidine/decitabine** or **Clinical trial**
      - **No response**
      - **Azacytidine/decitabine** or **Clinical trial**
      - **No response**
      - **IST** or **Clinical trial** or **Consider allotransplant for selected INT-1 patients**

- **Thrombocytopenia, neutropenia**
  - Serum Epo > 500 mU/ml
    - **Poor probability to respond to IST**
      - **Follow appropriate pathway below**
      - **Clinical trial** or **Consider allotransplant for selected INT-1 patients**

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Progressive Disease - See INT-2, HIGH (MDS-5)**
**IPSS CATEGORY**

**INT-2, HIGH**

**TREATMENT**

- **Transplant candidate and Donor available**
  - Yes → Allogeneic hemopoietic stem cell transplant (HSCT)
  - No → High intensity therapy or Azacytidine/decitabine or Clinical trial

- **Not intensive therapy candidate**
  → Azacytidine/decitabine or Clinical trial or Supportive care

---

**INT-2, HIGH**

- **Intensive therapy**
  - **Yes** → Allogeneic hemopoietic stem cell transplant (HSCT)
  - **No** → Azacytidine/decitabine or Clinical trial

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**See IPSS Classification System (MDS-3).**

**See Supportive Care (MDS-A).**

**Based on age, performance status, major comorbid conditions, psychosocial status and availability of caregiver.**

**Azacytidine or decitabine treatment may be used as a bridge to transplant while awaiting improved patient status or donor availability.**

**INT-1 patients with severe cytopenias would also be considered candidates for allogeneic HSCT.**

---

**Y High-Intensity Therapy:**

- Clinical Trials (preferred)
- Investigational therapy preferred.
- Standard induction therapy if investigational protocol unavailable or as a bridge to HSCT.
- (See text for more detail)
- Hemopoietic stem cell transplant (HSCT):
  - allogeneic-matched sibling including standard and (experimental) reduced intensity preparative approaches or matched unrelated donor (MUD)
EVALUATION OF RELATED ANEMIA

- H&P
- CBC, platelets, differential, reticulocyte count
- Examination of peripheral smear
- Bone marrow aspiration with iron stain + biopsy + cytogenetics
- Serum EPO level
- Consider HLA-DR 15 typing
- Rule out coexisting causes

TREATMENT OF SYMPTOMATIC ANEMIA

<table>
<thead>
<tr>
<th>del(5q) ± other cytogenetic abnormalities</th>
<th>Lenalidomide</th>
</tr>
</thead>
<tbody>
<tr>
<td>No response(^{aa}) \n</td>
<td>Continue EPO, decrease dose to tolerance</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Less than 15% ringed sideroblasts: Serum EPO (\leq 500) mU/ml</th>
<th>rHu EPO 40,000 - 60,000 U 1-3 x/wk subcutaneous or Darbepoetin alfa 150-300 mcg/wk subcutaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>No response(^{bb}) (despite adequate iron stores) \n</td>
<td>Consider adding G-CSF 1-2 mcg/kg 1-3 x/wk subcutaneous</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ringed sideroblasts ((\geq 15%)): Serum EPO (\leq 500) mU/ml</th>
<th>rHu EPO 40,000 - 60,000 U 1-3 x/wk subcutaneous + G-CSF 1-2 mcg/kg 1-3 x/wk subcutaneous or Darbepoetin alfa 150-300 mcg/wk subcutaneous + G-CSF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response(^{z}) \n</td>
<td>Decrease dose to tolerance</td>
</tr>
<tr>
<td>No response(^{bb}) \n</td>
<td>See Low, INT-1 (MDS-4)</td>
</tr>
</tbody>
</table>

| Serum EPO > 500 mU/ml | See Serum EPO > 500 mU/ml (MDS-4) |

FOLLOW-UP

- No response\(^{bb}\) \n- See Low, INT-1 (MDS-4)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

- Lack of 1.5 gm/dl rise in Hb or decreased RBC transfusion requirement by 3-4 months of treatment.
- Lack of 1.5 gm/dl rise in Hb or decreased RBC transfusion requirement by 6-8 weeks of treatment.
- Target hemoglobin up to 12gm/dl.
SUPPORTIVE CARE

- Clinical monitoring
- Psychosocial support
- Quality-of-life assessment

- Transfusions:
  - RBC transfusions (leuko-reduced) for symptomatic anemia, platelet transfusions for thrombocytopenic bleeding, irradiated products suggested for transplant candidates
  - CMV negative blood products are recommended whenever possible for CMV negative transplant candidates

- Antibiotics for bacterial infections
- Aminocaproic acid or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusions or profound thrombocytopenia

- Iron Chelation:
  - If > 20-30 RBC transfusions received, consider daily chelation with deferoxamine SC or deferasirox orally to decrease iron overload, particularly for LOW/INT-1 and for potential transplant patients. For patients with serum ferritin levels > 2500 ng/ml, aim to decrease ferritin levels to <1000 ng/ml.

- Cytokines:
  - EPO See Anemia pathway (MDS-6)
  - G-CSF or GM-CSF
    - Not recommended for routine infection prophylaxis
    - Consider use if recurrent or resistant infections in neutropenic patient
    - Combine with EPO for anemia when indicated See Anemia Pathway (MDS-6)
    - Platelet count should be monitored

1 See NCCN Supportive Care Guidelines.
2 Clinical trials in MDS are currently ongoing with oral chelating agents.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Discussion

NCCN Categories of Consensus

Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

Category 3: The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

The myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by patients’ cytopenias and the potential for MDS to evolve into acute myeloid leukemia (AML). In the general population, MDS occur in 5 per 100,000 people. However, among individuals older than age 70, the incidence increases between 22 and 45 per 100,000 and increasing further with age.

Managing MDS is complicated by the generally advanced age of the patients (median ages range from 65 to 70 years old), the attendant non-hematologic comorbidities, and the older patients’ relative inability to tolerate certain intensive forms of therapy. In addition, when the illness progresses into AML, these patients experience lower response rates to standard therapy than patients with de novo AML.

Diagnostic Classification

Initial assessment of patients with suspected MDS requires careful assessment of their peripheral blood smear and blood counts, marrow morphology, duration of their abnormal blood counts, other potential causes for their cytopenias and concomitant illnesses (MDS-1). The French-American-British (FAB) classification initially categorized patients for the diagnostic evaluation of MDS. Dysplastic changes in at least two of the three hematopoietic cell lines have been used by most histopathologists to diagnose MDS. These changes include megaloblastoid erythropoiesis, nucleocytoplasmic asynchrony in the early myeloid and erythroid precursors, and dysmorphic megakaryocytes. Patients with MDS are classified as having one of five subtypes of disease: refractory anemia (RA); RA with ringed sideroblasts (RARS); RA with excess of blasts (RAEB); RAEB in transformation (RAEB-T); and chronic myelomonocytic leukemia (CMML). MDS are generally indolent, with patients' blood counts remaining relatively stable over at least several months.

With a moderate degree of variability, RAEB patients (those with 5% to 20% marrow blasts) and those with RAEB-T (20% to 30% marrow blasts) generally have a relatively poor prognosis, with a median survival ranging from 5 to 12 months. In contrast, RA patients (fewer than 5% blasts) or RARS patients (fewer than 5% blasts plus more than 15% ringed sideroblasts) have a median survival of approximately 3 to 6 years. The proportion of these individuals whose disease transforms to AML ranges from 5% to 15% in the low-risk RA/RARS group to 40% to 50% in the relatively high-risk RAEB/RAEB-T group. The FAB classification categorizes patients with more than 30% marrow blasts as having AML.

In a study evaluating time-to-disease evolution, 25% of RAEB cases and 55% of RAEB-T cases underwent transformation to AML at 1 year, whereas 35% of RAEB cases and 65% of RAEB-T cases underwent...
transformation to AML at 2 years. In contrast, the incidence of transformation for RA was 5% at 1 year and 10% at 2 years. None of the RARS patients developed leukemia within 2 years.

Chronic myelomonocytic leukemia is categorized as MDS, although it often has the characteristics of a myeloproliferative disorder. Some groups have separated these patients into proliferative or non-proliferative/dysplastic subtypes, with prognosis mostly depending on the proportion of marrow blasts. Patients with the dysplastic form are classified within the FAB subtypes based on their percent marrow blasts. Within the RAEB and CMML subgroups, an increased proportion of marrow blasts has negative prognostic significance.

In 2002, the World Health Organization (WHO) proposed a new classification for MDS (MDS-2). This report suggests modifying the FAB definitions of MDS. Although most prior data require at least two-line dysplasia for the diagnosis of MDS, the WHO guidelines accept unilineage dysplasia for the diagnosis of RA and RARS provided that other causes of the dysplasia are absent and the dysplasia persists for at least 6 months. To establish the diagnosis of MDS, careful morphologic review and correlation with the patient’s clinical features are important, because a number of medications and viral infections (including HIV infection) may cause morphologic changes in marrow cells similar to MDS.

Other categories within the WHO proposal include refractory cytopenia with multilineage dysplasia (RCMD), separating RAEB patients into those with less than 10% marrow blasts (RAEB-1) and those with 10% or more marrow blasts (RAEB-2), 5q minus [del(5q)] syndrome, and MDS unclassified (with or without ringed sideroblasts). The category myelodysplastic syndromes/myeloproliferative disorders (MDS/MPD) is used for patients who previously have been classified as having CMML. The MDS/MPD category includes CMML, atypical CML, and juvenile myelomonocytic leukemia (JMML) as disorders having overlapping dysplastic and proliferative features. CMML had been categorized by FAB as MDS; by the International MDS Risk Analysis Workshop (IMRAW) as proliferative type (WBC ≥12,000/mm³) (a myeloproliferative disorder (MPD) or non-proliferative type (dysplastic MDS). The del(5q) syndrome, recognized by WHO as a separate MDS category, includes patients with an isolated 5q31-33 deletion and marrow showing <5% blasts, often with thrombocytosis. This disorder generally has a relatively good prognosis and is highly responsive to lenalidomide therapy.

The WHO proposal excludes RAEBT patients from MDS (proposing that AML should now include patients with 20% or more marrow blasts, rather than the previously used 30% or more cutoff). However, MDS are not only related to blast quantitation, but also possess a differing pace of disease related to distinctive biologic features that differ from de novo AML. In addition, therapeutic responses generally differ between these two patient groups.

Information from the International MDS Risk Analysis Workshop (IMRAW) with its International Prognostic Scoring system (IPSS) diagnostic classification provides data indicating that patients in IPSS Intermediate-2 and High categories are relatively high-risk, whereas Low and Intermediate-1 patients are in relatively low-risk prognostic categories (MDS-3).

The decision to treat patients having marrow blasts in the range of 20% to 30% with intensive AML therapy is thus complex and should be individualized. The clinician should consider such factors as age, antecedent factors, cytogenetics, comorbidities, pace of disease, and performance status. To aid this approach and given the long-standing experience with the FAB categorization, the NCCN MDS panel members currently endorse reporting and using both the FAB and the WHO classification systems. Thus, RAEBT patients may be considered as...
either MDS or AML. Studies have provided evidence supportive of the use of the WHO proposals.\textsuperscript{13,14}

AML evolving from MDS (AML-MDS) is often more resistant to standard cytotoxic chemotherapy than is de novo AML, which arises without antecedent hematologic disorder. High-risk MDS, AML-MDS, and some elderly patients with AML may have a more indolent course in terms of short-term progression compared with patients with standard presentations of de novo AML. Separate protocols for treating patients with standard presentation of de novo AML and for these other patient groups (such as MDS-AML, elderly AML, and high-risk MDS groups) seem appropriate. Clinical trials (investigational therapy) are preferable for these latter patient groups.

The recent update of the WHO morphologic proposals have helped clarify the clinical differences between the FAB RAEBT patients and AML. The current WHO classification lists the entity ‘AML with myelodysplasia-related changes’, which encompasses patients with AML post-MDS, AML with multilineage dysplasia and AML with MDS-associated cytogenetic abnormalities.\textsuperscript{15} These proposals state that some patients with AML with myelodysplasia-related changes having 20-29% marrow blasts, especially those arising from MDS, considered RAEBT by the FAB classification, may behave in a manner more similar to MDS than to AML.

To assist in providing consistency in diagnostic guidelines of MDS, an International Consensus Working Group recommended that minimal diagnostic criteria for this disease include required diagnostic prerequisites: stable cytopenia (for at least 6 months unless accompanied by a specific karyotype or bilineage dysplasia, in which case only 2 months of stable cytopenias are needed) and the exclusion of other potential disorders as a primary reason for dysplasia or/and cytopenia. In addition to these two diagnostic prerequisites, the diagnosis MDS requires at least one of three MDS-related (decisive)
criteria: i) dysplasia (≥10% in one or more of the three major bone marrow lineages), ii) a blast cell count of 5-19%, and iii) a specific MDS-associated karyotype, e.g. del(5q), del(20q), +8, or -7/del(7q). Further, several co-criteria help confirm the diagnosis of MDS. These co-criteria include studies with flow cytometry, bone marrow histology and immunohistochemistry, or molecular markers [to detect or exclude abnormal CD34 antigenic expression, fibrosis, dysplastic megakaryocytes, atypical localization of immature progenitors (ALIP), myeloid clonality].\textsuperscript{16}

**Initial Evaluation**

Several types of evaluations are needed to determine the clinical status of patients with MDS. Understanding clinical status is necessary for determining diagnostic and prognostic categorization and deciding treatment options. Clinical history should include the timing, severity, and tempo of abnormal cytopenias; prior infections or bleeding episodes; and number of transfusions. Concomitant medications and comorbid conditions require careful assessment. Because MDS are relatively indolent disorders, blood count stability is used to distinguish MDS from evolving AML. Other possible causes for patients’ cytopenias also require careful evaluation (MDS-1).

In addition to establishing current blood and reticulocyte counts, clinicians need a peripheral blood smear evaluation to determine the degree of dysplasia and, thus, potentially dysfunctional cells. Bone marrow aspiration with Prussian blue stain for iron and biopsy are needed to evaluate the degree of hematopoietic cell maturation abnormalities and relative proportions, percentage of marrow blasts, marrow cellularity, presence or absence of ringed sideroblasts (and presence of iron per se), and fibrosis. Marrow cytogenetics should be obtained because they are of major importance for prognosis.
Other useful screening laboratory studies include serum erythropoietin (sEpo), vitamin B₁₂, red blood cell folate levels, and serum ferritin. Serum ferritin levels may be nonspecific, particularly in the face of inflammatory conditions such as rheumatoid arthritis. Therefore, in such cases, obtaining the serum iron levels and total iron binding capacity (TIBC) along with serum ferritin may be helpful.

If patients require platelet transfusions for severe thrombocytopenia, human leukocyte antigen (HLA) typing (A, B) may be helpful. For hematopoietic stem cell transplant (HSCT) candidates, the patient’s CMV status and full HLA typing (A, B, C, DR, and DQ) of the patient and potential donors are needed. Bone marrow flow cytometry for assessing the % of CD34+ cells (blast cells are usually CD34+), and HIV screening, if clinically indicated, may also be valuable in some clinical situations. The screening for paroxysmal nocturnal hemoglobinuria (PNH) and HLA-DR15 is potentially useful for determining which patients may be more responsive to immunosuppressive therapy, particularly in young patients with normal cytogenetics and hypoplastic MDS (see Prognostic Stratification below).

Bone marrow biopsy staining for reticulin is helpful for evaluating the presence and degree of bone marrow fibrosis. Flow cytometry studies should be used to determine the presence of a PNH clone or to assess the possibility of large granular lymphocytic (LGL) disease. Review of peripheral smear to determine the presence of LGL is important in this regard.

Additional genetic screening should be considered for patients with familial cytopenias. This will help in evaluating for Fanconi’s anemia or dyskeratosis congenita. In addition, this information is of clinical importance as familial MDS is associated with chromosomal fragility and therefore these patients may respond differently to hypomethylating agents and, more importantly, family members may not be eligible as donors for allogeneic hematopoietic stem cell transplant.

Determination of PDGFRβ gene rearrangements in CMML/MPD patients with 5q31-33 translocations is helpful for evaluating these patients (MDS-1). The activation of this gene encoding a receptor tyrosine kinase for platelet-derived growth factor receptor beta (PDGFRβ) has been shown in some of these patients. Data have indicated that MPD/CMML patients with such PDGFRβ fusion genes may respond well to treatment with Imatinib mesylate.

The frequency of activating mutations of the tyrosine kinase known as Janus Kinase (JAK2) in MDS and de novo AML is lower compared to myeloproliferative disorders. If one encounters thrombocytosis in patients with MDS, screening for JAK2 mutations may be helpful. A positive test for JAK2 mutation is consistent with presence of a myeloproliferative component of their disorder.

Recent flow cytometric studies suggest the potential utility of this methodology for characterizing MDS marrow blast cells and as an aid for assessing prognosis of these patients. However, due to the non-standardized nature of these analyses, further investigations are warranted prior to suggesting their routine use.

Prognostic Stratification

Despite its value for diagnostic categorization of patients with MDS, the prognostic limitations of the FAB classification have become apparent with quite variable clinical outcomes within the FAB subgroups. The morphologic features contributing to this variability include the wide range of marrow blast percentages for patients with RAEB (5% to 20%) and CMML (1% to 20%); lack of inclusion of critical biologic determinants such as marrow cytogenetics; and the degree and number of morbidity-associated cytopenias. These well-perceived
problems for categorizing patients with MDS have led to the development of additional risk-based stratification systems.27

The International Prognostic Scoring System (IPSS) for primary MDS emerged from deliberations of the IMRAW (MDS-2).8,9 Compared with previously used systems, the risk-based IPSS has markedly improved prognostic stratification of MDS cases. In this analysis, cytogenetic, morphologic, and clinical data were combined and collated from a relatively large group of MDS cases that had been included in previously reported prognostic studies.8,27 FAB morphologic criteria were used to establish the diagnoses of MDS. In addition, relative stability of peripheral blood counts for 4 to 6 weeks was needed to exclude other possible etiologies for the cytopenias, such as drugs, other diseases, or incipient evolution to AML. CMML was subdivided into proliferative and non-proliferative subtypes. Patients with proliferative type CMML (those with white blood cell counts greater than 12,000/mcL) were excluded from this analysis.8 Patients with non-proliferative CMML (with white blood cell counts of 12,000/mcL or less as well as other features of MDS) were included in the analysis.28

Significant independent variables for determining outcome for both survival and AML evolution were found to be marrow blast percentage, number of cytopenias, and cytogenetic subgroup (good, intermediate, poor). Patients with the chromosome anomalies t(8;21) or inv16 are considered to have AML and not MDS, regardless of the blast count. Age was also a critical variable for survival, although not for AML evolution. The percentage of marrow blasts was divisible into four categories: 1) less than 5%, 2) 5% to 10%, 3) 11% to 20%, and 4) 21% to 30%.

Cytopenias were defined for the IPSS as having hemoglobin level less than 10 g/dL, an absolute neutrophil count (ANC) below 1,800/mcL, and platelet count below 100,000/mcL. Patients with normal marrow karyotypes, del(5q) alone, del(20q) alone, and -Y alone had relatively good prognoses (70%), whereas patients with complex abnormalities (three or more chromosome anomalies) or chromosome 7 anomalies had relatively poor prognoses (16%). The remaining patients were intermediate in outcome (14%). Of the patients in the “complex” category, the vast majority had chromosome 5 or 7 abnormalities in addition to other anomalies.

To develop the IPSS for MDS, relative risk scores for each significant variable (marrow blast percentage, cytogenetic subgroup, and number of cytopenias) were generated8 (MDS-2). By combining the risk scores for the three major variables, patients were stratified into four distinctive risk groups in terms of both survival and AML evolution: low, intermediate-1 (INT-1), intermediate-2 (INT-2), and high.

When either cytopenias or cytogenetic subtypes were omitted from the classification, discrimination among the four subgroups was much less precise. Both for survival and AML evolution, the IPSS showed statistically greater prognostic discriminating power than earlier classification methods, including the FAB system.8

Recent data have indicated that additional clinical variables are additive to the IPSS regarding prognosis for MDS patients. The WHO prognostic scoring system (WPSS) incorporates the WHO-based morphologic categories, the IPSS cytogenetic categories and the patients’ need or lack of RBC transfusion dependence.29 This system demonstrated that the requirement for RBC transfusions is a negative prognostic factor for patients in the lower risk MDS categories. In addition, depth of anemia per se has additive and negative prognostic import for the intermediate IPSS categories.30

Therapeutic Options

The patient’s IPSS risk category is used in planning therapeutic options because it provides a risk-based patient evaluation. In addition, the patient’s age and performance status are critical determinants because
they have a major influence on the patient's ability to tolerate certain intensive treatments.

If the patient was only recently evaluated, determining the relative stability of the patient’s blood counts over several months is important to assess whether the patient’s disease progresses, including incipient transformation to AML. In addition, this assessment permits determination of other possible etiologies for cytopenias. The patient’s preference for a specific approach is also important in deciding treatment options. The therapeutic options for MDS include supportive care, low-intensity therapy, high-intensity therapy, and/or clinical trial (MDS-4, MDS-5). In evaluating results of therapeutic trials the panel found it important for studies to use the standardized International Working Group (IWG) response criteria.31,32

For the MDS therapeutic algorithm, all patients should receive relevant supportive care (MDS-4, MDS-6, and MDS-A). Following that, the panel has proposed initially stratifying patients with clinically significant cytopenia(s) into two major risk groups: (1) relatively lower-risk patients who are in the IPSS Low, Intermediate-1 category (MDS-4), and (2) higher risk patients in the IPSS Intermediate-2/ High categories (MDS-5). Per IWG response criteria, for patients in the lower risk group, the major therapeutic aim would be hematologic improvement, whereas for those in the higher risk group alteration of the disease natural history is viewed as paramount. Cytogenetic and quality of life responses are also important parameters to assess.

Supportive Care

Currently, the standard of care in the community for MDS includes supportive care (MDS-A and NCCN Supportive Care Guidelines). This entails observation, clinical monitoring, psychosocial support, and quality-of-life (QOL) assessment. Major efforts should be directed toward addressing the relevant QOL domains (e.g., physical, functional, emotional, spiritual, social) which adversely affect the patient. Supportive care should include red blood cell transfusions for symptomatic anemia as needed (generally leukocyte-reduced) or platelet transfusions for severe thrombocytopenia or thrombocytopenic bleeding. There was non-uniform consensus among the panel members based on differing institutional policies regarding the necessity for routine irradiation of blood products used in patients with MDS; however, the panel agreed that all directed-donor products and transfused products for potential stem cell transplant patients should be irradiated. Additionally, CMV negative blood products are recommended whenever possible for CMV negative recipients. Aminocaproic acid or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusions or profound thrombocytopenia.

Management of Iron Overload

For relatively low-risk patients with excessive iron accumulation resulting from the number of red blood cell transfusions received, iron chelation therapy should be instituted.33

Although the specific therapies patients receive may alleviate RBC transfusion need, a substantial proportion of MDS patients may not respond to these treatments and may develop iron overload as well as its consequences.34 Thus, effective treatment of such transfusional siderosis in MDS patients is quite germane. Studies in patients requiring relatively large numbers of RBC transfusions (e.g., thalassemia and MDS) have demonstrated the pathophysiology and adverse effects of chronic iron overload on hepatic, cardiac and endocrine function. Increased non-transferrin bound iron (NTBI) levels, generated when plasma iron exceeds transferrin's binding capacity, combines with oxygen to form hydroxyl and oxygen radicals. These toxic elements cause lipid peroxidation and cell membrane, protein, DNA and organ damage.35,36
Reversal of some of the consequences of iron overload in MDS and other iron overload states (e.g., thalassemia) by iron chelation therapy have been shown in patients in whom the most effective chelation occurred.\textsuperscript{31,35} This included transfusion independence, in a portion of a small group of carefully studied MDS patients who had undergone effective deferoxamine (DFO) chelation for 1-4 years.\textsuperscript{37} In addition, improvement in cardiac iron content was demonstrated in these patients after chelation.\textsuperscript{38} Data have shown decreased survival for RBC transfusion dependent low-risk patients compared to those patients not requiring transfusions.\textsuperscript{39} Such findings have major implications for altering the morbidity of MDS patients, particularly those with pre-existing cardiac or hepatic dysfunction.

Thus, the use of DFO for such patents is highly recommended. This is generally administered for patients who have previously received 20-30 units of RBCs, for whom ongoing RBC transfusions are anticipated and for those with serum ferritin levels >2,500 mcg/L. This treatment is predominantly used for patients with relatively lower risk MDS, whose clinical course suggests ongoing chronic RBC transfusion need, and for those with concurrent cardiac or hepatic dysfunction. Monitoring serum ferritin may be useful, aiming to decrease ferritin levels to <1,000 mcg/L. It is recognized that such measurements, though useful, are less precise than SQUID (Superconducting Quantum Interference Device) or the more recent development of specific measurement of hepatic MRI evaluations of hepatic iron content.\textsuperscript{40,41}

Treatment with DFO is generally given as 1-2 gm by overnight subcutaneous (SC) infusion 5-7 nights weekly. An alternate form of administration has been the use of 1-2 gm bid SC bolus administration. Due to the short half-life of the DFO, IV bolus administration is generally not useful for chronic iron overload. Careful monitoring of eye, ear and renal function is needed for patients treated with DFO. However, it is understood that due to the logistical difficulties of chronic lengthy SC infusions of DFO in the generally elderly MDS patients who also have a variety of comorbidities, such therapy is often begun late and with limited enthusiasm, both by patient and physician. For patients with chronic RBC transfusion need, serum ferritin levels and associated organ dysfunction (heart, liver, and pancreas) should be monitored.

The current clinical availability of two oral iron chelators deferiprone, L1\textsuperscript{42} and deferasirox/ICL670 \textsuperscript{43,44} now provides potentially useful drugs for more readily treating this iron overload state. Deferiprone is not available in the US. In Europe, deferiprone is licensed for treatment of iron overload in patients with $\beta$-thalassemia when DFO is inadequate or contraindicated. Agranulocytosis occurs in low incidence but remains a concern with deferiprone.\textsuperscript{45}

Deferasirox/ICL670 has been approved by the FDA for treatment of iron overload. Clinical trials in MDS are ongoing with oral iron chelating agents. The NCCN MDS panel members recommend strongly considering chelation with deferoxamine SC or deferasirox/ICL670 orally to decrease iron overload in low or intermediate-1 patients who have received or are anticipated to receive greater than 20 RBC transfusions, for whom ongoing RBC transfusions are anticipated and for those with serum ferritin > 2500 ng/mL, aiming to decrease ferritin levels to < 1,000 ng/ml (MDS-A).

Hematopoietic cytokine support should be considered for refractory symptomatic cytopenias.\textsuperscript{46} For example, recombinant human granulocyte colony stimulating factor (G-CSF) or granulocyte-monocyte CSF (GM-CSF) treatment could be considered for neutropenic MDS patients with recurrent or resistant bacterial infections. The use of recombinant human erythropoietin to treat symptomatic anemia is discussed under MDS-6 and “Evaluation and Treatment of Related Anemia”.
Low-Intensity Therapy

Low-intensity therapy includes the use of low-intensity chemotherapy or biologic response modifiers. Although this type of treatment is mainly provided in the outpatient setting, supportive care or occasional hospitalization (for example, for treatment of infections) may be needed after certain of these treatments.

Hypo-methylating Agents

As a form of relatively low-intensity chemotherapy, the DNA methyl transferase inhibitor (DMTI) hypo-methylating agents 5-azacytidine (Aza-C) and decitabine (5-aza-2’-deoxycytidine) have been shown in randomized phase III trials to decrease the risk of leukemic transformation, and, in a portion of the patients, to improve survival.\(^ {47,48}\) For Aza-C, hematologic responses occurred in 60% of patients in the azacitidine arm (7% complete response, 16% partial response, 37% improved) compared with an overall 5% response rate in those receiving supportive care. Additionally, the time to progression to AML or death was improved in those who received Aza-C earlier in the course of disease, suggesting that the drug prolonged the duration of stable disease. Subsequently Silverman and colleagues provided a summary of three studies of Aza-C in a total of 306 patients with high risk MDS.\(^ {49}\) In this analysis, which included patients receiving either subcutaneous or intravenous delivery of the drug, complete remissions were seen in 10% to 17% of Aza-C treated patients; partial remissions were rare; 23% to 36% of patients had hematologic improvement. The authors concluded that Aza-C provided important clinical benefits for patients with high-risk MDS. Recent preliminary data from a randomized trial for higher risk MDS indicated that Aza-C was superior to conventional care (standard chemotherapy or supportive care) regarding overall survival.\(^ {50}\)

Aza-C therapy should be considered for treating MDS patients with progressing or relatively high-risk disease. The drug is generally administered at a dose of 75mg/m\(^2\)/d SC x7 days monthly for at least 4-6 courses. Treatment courses may need to be extended further or may be used as a bridging therapy to more definitive therapy (e.g., HSCT, for patients whose marrow blast counts require lowering prior to that procedure). This drug has been approved by the FDA for treatment of MDS patients.

Similarly, the other DMTI hypomethylating agent, decitabine, given intravenously and administered with a regimen which required hospitalization of patients, has also shown encouraging results for the therapy of patients with higher risk MDS. As the treatment regimen was generally associated with low intensity-type toxicities it is also considered to be Low Intensity Therapy. The drug has shown cytogenetic conversion in approximately 30% of patients,\(^ {51,52}\) with an overall response rate of 49%, and a 64% response rate in patients with a high-risk IPSS score. Comparison of results of these studies with those of 5-azacytidine showed a substantial level of similarity.\(^ {53,54}\)

The results of a Phase III randomized trial of decitabine [15mg/m\(^2\) IV infusion over 3 hours every 8 hours (i.e., 45mg/m\(^2\)/day) on 3 consecutive days every 6 wks for up to 10 cycles] vs. supportive care (SC) in adult primary and secondary MDS patients with IPSS Int-1 (31%), Int-2 (44%) and High (26%) risk disease indicated higher response rates, remission duration, time to AML progression and survival benefit in patients with Int-2 and High risk subtypes.\(^ {48,53}\) Overall response rates (CR + PR) were 17% with an additional 13% having hematologic improvement. The probability of progression to AML or death was 1.68-fold greater for SC patients than for those receiving decitabine. Based on this study and three supportive Phase II trials,\(^ {48,55}\) the drug has also been approved by the FDA for treating MDS patients.

Alternate dosing regimens using lower doses of decitabine administered in an outpatient setting are currently being evaluated.\(^ {56}\) In 2007 Kantarjian and colleagues provided an update of their results in
115 patients with higher risk MDS using alternative and lower dose decitabine treatment regimens.\textsuperscript{57} Patients received 1 of 3 different schedules of decitabine, including both subcutaneous and IV administration and received a mean of 7 courses of therapy. Responses were improved with this longer duration of therapy. Overall, 80 patients (70\%) responded with 40 patients (35\%) achieving a complete response and 40 (35\%) achieving a partial response. The median remission duration was 20 months, and the median survival was 22 months. Kantarjian and colleagues also compared the three different schedules of decitabine in a randomized study of 95 patients with MDS or CMML, receiving either 20 mg/m\textsuperscript{2} intravenously daily for 5 days; 20 mg/m\textsuperscript{2} subcutaneously daily for 5 days; or 10 mg/m\textsuperscript{2} intravenously daily for 10 days.\textsuperscript{58} The 5-day intravenous schedule was considered the optimal schedule; the complete response rate in this arm was 39\%, compared with 21\% in the 5-day subcutaneous arm and 24\% in the 10-day intravenous arm (P < .05).

Currently, azacytidine and decitabine are considered to be therapeutically relatively similar. ‘Failure to respond to hypomethylating agents’ is considered if there is lack of CR, PR, hematologic improvement or frank progression to AML, in particular with loss of control (proliferation) of peripheral counts, or excess toxicity that precludes continuation of therapy. The minimum number of courses prior to considering the treatment a failure should be 4-6 courses.

As data have predominantly indicated altered natural history and decreased evolution to AML in responders, the major candidates for these drugs are MDS patients with Intermediate-2 or High risk disease (MDS-5). Such candidates include the following:

- Patients who are not candidates for high intensity therapy.
- Patients who are potential candidates for allogeneic HSCT but for whom delay in receipt of that procedure is anticipated (e.g., due to need to further reduce the blast count, time to improve the patient’s performance status or delay in availability of a donor). In these circumstances, the drugs may be used as bridging therapy for that procedure.

### Biologic Response Modifiers and Immunosuppressive Therapy

The non-chemotherapy low-intensity agents (biologic response modifiers), currently available, include: anti-thymocyte globulin (ATG), cyclosporin, thalidomide, lenalidomide, anti-TNF receptor fusion protein, and vitamin D analogues, all of which have shown some efficacy in phase I and phase II trials.\textsuperscript{1,59-65}

Use of anti-immune type therapy with ATG with or without cyclosporin\textsuperscript{59,60} has been shown in several studies to be most efficacious in MDS patients with HLA-DR15 histocompatibility type, marrow hypoplasia, normal cytogenetics, low-risk disease, and evidence of a PNH clone.\textsuperscript{17,18} The NIH group has updated their analysis of 129 patients treated with immunosuppressive therapy (IST). The patients were treated with antithymocyte globulin (ATG) and cyclosporine alone or in combination.\textsuperscript{66} This study demonstrated markedly improved response rates in younger (≤60 years old) and intermediate 1 patients as well as in those with high response probability characteristics as indicated by their prior criteria (HLADR15+, age and number of transfusions).\textsuperscript{66}

Encouraging data have been presented for treating lower risk MDS patients with lenalidomide.\textsuperscript{10,67} Beneficial results have been particularly evident for patients with del(5q) chromosomal abnormalities.\textsuperscript{10,67,68} In a multicenter phase II trial of lenalidomide, given at a dose of 10 mg/day for 21 days or 10 mg/day, in 148 anemic RBC transfusion-dependent MDS patients with del(5q), with or without additional cytogenetic abnormalities, RBC transfusion independence (assessed at 24 weeks) occurred in 66\% of patients with Low/Intermediate-1 compared with 52\% of patients with higher risk disease.\textsuperscript{10} Cytogenetic responses were
achieved in 76% of patients; 55% had a complete cytogenetic response. However, along with these results were common adverse events (in ~50% of patients) that required treatment interruption or dose reduction for potentially serious but generally transient neutropenia and/or thrombocytopenia. Thus, careful monitoring of the patients’ blood counts during the treatment period is mandatory when using this agent, particularly in patients with renal dysfunction (due to the drug’s renal route of excretion). This drug has recently been approved by the FDA for treatment of MDS patients with del(5q).

A recent phase II study evaluated lenalidomide treatment in 214 transfusion-dependent patients with low- or int-1-risk MDS without the 5q- deletion. Results showed 26% of the non-(del) 5q patients (56 of 214) achieved transfusion independence (TI) after a median of 4.8 weeks of treatment. TI continued for a median duration of 41 weeks. The median rise in hemoglobin was 3.2 g/dL (range 1.0 to 9.8 g/dL) for those achieving TI. A ≥50% reduction in transfusion requirement was noted in an additional 37 patients (17%), yielding an overall rate of hematologic improvement of 43%. The most common grade 3/4 adverse events were neutropenia (30%) and thrombocytopenia (25%). Further evaluation in more extended clinical trials is needed to determine the efficacy of this drug and other agents for non-del(5q) MDS patients. The NCCN MDS panel members recommend lenalidomide be considered for treatment of symptomatically anemic non-del(5q) patients whose anemia did not respond to initial therapy.

High-Intensity Therapy

High-intensity therapy includes intensive induction chemotherapy, or hematopoietic stem cell transplantation (HSCT). Although these approaches have the potential to change the natural history of the disease, they also have an attendant greater risk of regimen-related morbidity and mortality. The panel recommends that such treatments be given in the context of clinical trials. Recent comparative studies have not shown benefit between several different intensive chemotherapy regimens (including idarubicin-, cytarabine-, fludarabine-, and topotecan-based regimens) in MDS.

A high degree of multi-drug resistance occurs in marrow hematopoietic precursors from patients with advanced MDS, with associated decreased responses and shorter response durations with many standard treatment regimens of induction chemotherapy. Thus, chemotherapeutic agents used to treat “resistant-type” AML, and agents that modulate this resistance, are now being evaluated for treating patients with advanced MDS. Although several studies using multi-drug resistance modulators were positive in this setting, others were not. Further clinical trials evaluating other multi-drug resistance modulators are ongoing.

Allogeneic hematopoietic stem cell transplant (HSCT) from a HLA-matched sibling donor is a preferred approach for treating a portion of patients with MDS, particularly those with high-risk disease. Matched non-myeloablative transplant regimens and matched unrelated donor stem-cell transplants are becoming options at some centers to treat these patients. In certain investigative settings, autologous bone marrow or peripheral blood stem cell transplantation is being considered. Whether transplants should be performed before or after patients achieve remission after induction chemotherapy has not been established. Comparative clinical trials are needed to determine these points.

Recommended Treatment Approaches

Therapy for Lower Risk patients (IPSS Low/Intermediate-1)

Regarding the algorithm for therapeutic options for the lower risk patients with clinically significant cytopenias, the panel recommends stratifying these patients into several groups (MDS-4). Those with
del(5q) chromosomal abnormalities and symptomatic anemia should receive lenalidomide. Other patients with symptomatic anemia are categorized on the basis of their levels of serum erythropoietin (sEpo). Those with levels ≤500 mU/ml should be treated with recombinant human Epo (Epo) or darbepoeitin with or without granulocyte colony stimulating factor (G-CSF) (see section on Evaluation and Treatment of Related Anemia below and MDS-6). Non-responders should be considered for treatment with azacytidine or decitabine or for lenalidomide therapy. In addition, such patients or non-responders to this therapy could be considered for participation in a clinical trial with other relevant agents, or for allogeneic hematopoietic stem cell transplantation (HSCT) (see section on Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) below).

Anemic patients with sEpo level >500 should be evaluated to determine whether they have a good probability of responding to immunosuppressive therapy. The most appropriate candidates include those who are either ≤60 years old (with IPSS Low or int-1 MDS), are HLA-DR15+, have a PNH+ clone or have hypoplastic MDS. Immunosuppressive therapy consists of ATG with or without cyclosporin, or possibly cyclosporin alone. Non-responders to immunosuppressive therapy would be considered for treatment with azacytidine, decitabine, or a clinical trial. Patients with sEpo levels >500 who have a low probability of responding to immunosuppressive therapy should be considered for treatment with azacytidine, decitabine, or lenalidomide. Others or non-responders to that therapy could be considered for a clinical trial or for allogeneic hematopoietic stem cell transplantation. Patients with other serious cytopenias (particularly clinically severe thrombocytopenia) should be considered for treatment with azacytidine or decitabine or a clinical trial. Such patients, if they do not respond to this treatment, should be considered for treatment with immunosuppressive therapy, a clinical trial, or for allogeneic hematopoietic stem cell transplantation. (See section on Allogeneic Hematopoietic stem cell transplant (HSCT) below and MDS-5)

Careful monitoring for disease progression and consideration of the patient’s desires play major roles in the timing and decision to embark on treatment for Lower or Higher Risk disease (MDS-5).

Therapy for Higher Risk Patients (IPSS Intermediate-2/High)

Treatment for higher risk patients is dependent on whether they are felt to be candidates for intensive therapy (e.g., allogeneic HSCT or intensive chemotherapy) (MDS-5). Clinical features relevant for this determination include the patient’s age, performance status, absence of major comorbid conditions, psychosocial status, and availability of a suitable HSC donor and caregiver. In addition, the patient’s personal preference for type of therapy needs particular consideration. Supportive care (MDS-A) should be provided for all patients.

Intensive therapy

Allogeneic Hematopoietic stem cell transplant (HSCT)

The potential for patients’ receipt of an allogeneic HSCT (in addition to the patient’s age, performance status and IPSS score) is also dependent on whether a suitable donor is available and if the patient’s marrow blast count is sufficiently low (i.e., <10 or 20% blasts for some institutions and specific protocols). For those patients who are transplant candidates with an available donor, preference is for a matched sibling donor, although data using matched-unrelated donors is nearly comparable in selected patients. Standard conditioning is used for relatively younger patients whereas the experimental approach using non-myeloablative or reduced intensity transplant conditioning is preferable in older individuals.

To aid therapeutic decision-making regarding the timing and selection of MDS patients for HSCT, a recent study compared allogeneic sibling
matched HSCT data in MDS patients ≤60 years old to clinical outcomes to those of non-treated IMRAW/IPSS database MDS patients. Using Markov decision-making statistical analysis, this investigation indicated IPSS INT-2 and High risk patients ≤ 60 years old should proceed to such HLA identical sibling transplants at diagnosis, whereas for those Low or INT-1 MDS patients, it would be beneficial to delay transplantation for several years and prior to disease progression.\textsuperscript{92}

**Intensive chemotherapy**

For patients eligible for intensive therapy lacking a stem cell donor, or for those in whom the marrow blast count requires reduction, consideration should be given to the use of intensive induction chemotherapy.\textsuperscript{93} Although the response rate and durability of this treatment is lower than for standard AML, this treatment (particularly in clinical trials with novel agents) could be beneficial in a portion of the patients. For those patients with a potential stem cell donor who require reduction of their tumor burden (i.e., to decrease the marrow blast count), achievement of even a partial remission may be adequate to permit the HSCT. For this purpose, Aza-C, decitabine, or participation in clinical trials, are also available treatment options.

**Non-Intensive therapy**

For patients who are not candidates for intensive therapy, the use of azacytidine, decitabine, or a relevant clinical trial should be considered. As above for patients requiring a decrease in tumor burden prior to HSCT, for some patients eligible for such therapy, the use of azacitidine or decitabine may be a bridge to usefully decrease the marrow blast count enough to permit the transplant.

**Supportive Care only**

For patients with adverse clinical features or disease progression despite therapy and absence of reasonable specific anti-tumor therapy, good supportive care should be maintained (MDS-A).

**Evaluation and Treatment of Related Anemia**

Major morbidities of MDS include symptomatic anemia and its associated fatigue. Much progress has been made in improving the management of this anemia. However, along with giving specific treatment for anemia related to MDS, the health care provider must identify and treat any coexisting causes of anemia.

Standard assessments should be performed to look for other causes of anemia, such as gastrointestinal bleeding, hemolysis, renal disease, and nutritional deficiency. If needed, iron, folate, or vitamin B\textsubscript{12} studies should be obtained and the cause of depletion corrected if possible. After excluding these causes of the anemia and providing proper treatment for them, further consideration for treating the anemia related to MDS should be undertaken. Currently the standard of care for symptomatic anemic patients is red blood cell (RBC) transfusion support (using leuko-poor products). If the patient is a potential HSCT candidate, the panel recommends consideration of CMV negative (if the patient is CMV negative serologically) and irradiated transfused products.

Anemia related to MDS generally presents as a hypoprotective macrocytic anemia, often associated with suboptimal elevation of serum Epo levels.\textsuperscript{1,94} To determine FAB subtype, iron status, and the level of ringed sideroblasts, bone marrow aspiration with iron stain, biopsy, and cytogenetics should be examined. Patient also should be considered for HLA-DR15 typing as indicated above.

Individuals having symptomatic anemia and del(5q) with or without other cytogenetic abnormalities should receive a trial of lenalidomide. Those with normal cytogenetics and with <15% marrow ringed sideroblasts and serum Epo level ≤500 mU/mL may respond to Epo if relatively high doses of recombinant human Epo are administered.\textsuperscript{46,95,96} The Epo dose required is 40-000 - 60,000 units 1-3
times a week subcutaneously. Erythroid responses generally occur within 6 to 8 weeks of treatment. A more prompt response may be obtained by starting at the higher dose. This Epo dose is much higher than that needed to treat renal causes of anemia wherein marrow responsiveness would be relatively normal. If a response occurs, the recommendation is to continue this dose but attempt to decrease it to tolerance. The literature supports daily or 2-3 times per week dosing.

Iron repletion needs to be verified before instituting Epo or darbepoetin therapy. If no response occurs with these agents alone, the addition of G-CSF should be considered. Evidence suggests that G-CSF (and, to a lesser extent, GM-CSF) has synergistic erythropoietic activity when used in combination and markedly enhances the erythroid response rates. This is particularly evident for patients with ≥15% ringed sideroblasts in the marrow (and serum Epo level ≤500 mU/mL) as the very low response rates in this subgroup to Epo or darbepoetin alone are markedly enhanced when combined with G-CSF.

For the erythroid synergistic effect, relatively low doses of G-CSF are needed to help normalize the neutrophil count in initially neutropenic patients or to double the neutrophil count in patients who are initially normal. For this purpose, an average of 1-2 mcg/kg subcutaneously is administered daily or 1-3 times a week. Refrigerated multi-dose vials (withdrawing all contents at one time into separate syringes and leaving them in the refrigerator until used) permit more efficient use of G-CSF, decreasing its cost. Patients may be taught to self-administer the drug. Again, detection of erythroid responses generally occurs within 6 to 8 weeks of treatment. If no response occurs in this time frame, this treatment should be considered a failure and discontinued. If treatment failure occurs one should rule out and treat deficient iron stores. Clinical trial or supportive cares are also treatment options in this category of patients. A predictive and validated model has been developed for predicting erythroid responses to Epo plus G-CSF, based on the patient's basal serum Epo level and number of previous RBC transfusions. Improved quality of life has been demonstrated in responding patients. This cytokine treatment is not suggested for patients with endogenous serum Epo levels >500 mU/mL due to the very low erythroid response rate to these drugs.

Darbepoetin alfa is a longer-acting form of Epo. Studies predominantly with patients having lower risk MDS have demonstrated a substantial proportion of erythroid responses with the initial trials showing response rates of 40% and 60% (combined major and minor responses using IWG response criteria). Results of clinical trials in patients with MDS have suggested that the overall response rates to darbepoetin are similar to or possibly higher than to epoetin. These response rates may in part be due to the dosage used (150 to 300 mcg/kg/week subcutaneously) or to that fact that better risk patients were enrolled in studies of darbopoetin compared to epoetin. Features predictive of response have included relatively low basal serum Epo levels, low percentage of marrow blasts and relatively few prior RBC transfusions.

In March 2007 and 2008, the FDA announced alerts and strengthened safety warnings for the use of Erythropoiesis-Stimulating Agents (ESAs). They noted that increased mortality, possible tumor promotion and thromboembolic events were observed in non-MDS patients receiving ESAs when dosing has targeted hemoglobin levels >12 gm/dL (study patients had chronic kidney failure, had head and neck, advanced breast, lymphoid or non-small cell lung cancer and were receiving radiation therapy, were cancer patients not receiving chemotherapy, or were orthopedic surgery patients). However, as indicated above, ESAs have been used safely in large numbers of adult MDS patients and have become important for symptomatic improvement of those affected by the anemia caused by
this disease often with a decrease in RBC transfusion requirements. The NCCN MDS Practice Guidelines Panel recommendations for use of ESAs in MDS have evolved from these and more recent data. In addition, studies assessing the long term use of Epo with or without G-CSF in MDS patients compared to either randomized controls or historical controls have shown no negative impact on survival or AML evolution of such treatment. In addition, results of the studies by Jadersten et al. indicated improved survival in low risk MDS patients with low transfusion need treated with these agents. The study by Park et al. further indicated improved survival and decreased AML progression of IPSS Low/Int-1 patients treated with Epo/G-CSF compared to the historical control IMRAW database patients. Thus, these data do not indicate a negative impact of these drugs for treatment of MDS. Given these data, we endorse and re-iterate our prior recommendations for ESA use in the management of symptomatic anemia in MDS patients, but with a change in the target hemoglobin level—i.e., to aim for a target hemoglobin of ≤12gm/dl.

In July 2007, the Centers for Medicare and Medicaid Services (CMS) modified the scope of their decision regarding use of ESAs in cancer and related neoplastic conditions to make no national coverage determination (NCD) on the use of ESAs in MDS (i.e., not restricting ESA use in MDS through the NCD). Thus, local Medicare contractors may continue to make reasonable and necessary determinations on uses of ESAs that are not determined by the NCD.

Clinical trials with other experimental agents which are reportedly capable of increasing hemoglobin levels should be explored in patients not responding to standard therapy. These drugs should be used in the context of therapeutic approaches for the patient’s underlying prognostic risk group.

Summary
These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities, azacytidine and decitabine for treating higher risk or non-responsive MDS patients, and deferasirox for iron chelation of iron overloaded MDS patients. However, as a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietin cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient’s quality of life is important. Progress toward improving management of MDS has occurred over the past few years and more such advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

Disclosures for the NCCN Myelodysplastic Syndromes Guidelines Panel
At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers’ bureau participation. Members of the panel indicated that they have received support from the following: Alexion, Amgen, Bristol-Myers Squibb, Celgene, Comisa, CTI, Genentech, Genta, Inc., Genzyme, Johnson & Johnson, MGI, Novartis, Pharmion, Inc., Scios and SuperGen. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.
References


18. Saunthararajah Y, Nakamura R, Nam JM et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-1574.


77. Anderson JE, Thomas ED. The Seattle experience with bone marrow transplantation for MDS. Leuk Res 1997;21[suppl 1]:S51.


